Papi A, Papadopoulos N G, Stanciu L A, Degitz K, Holgate S T, Johnston S L
University Medicine, University of Southampton, Southampton, UK.
J Allergy Clin Immunol. 2001 Aug;108(2):221-8. doi: 10.1067/mai.2001.116861.
Rhinoviruses have been recently associated with the majority of asthma exacerbations for which current therapy is inadequate. Intercellular adhesion molecule 1 (ICAM-1) has a central role in airway inflammation in asthma, and it is the receptor for 90% of rhinoviruses. Rhinovirus infection of airway epithelium induces ICAM-1. Desloratadine and loratadine are compounds belonging to the new class of H(1)-receptor blockers. Anti-inflammatory properties of antihistamines have been recently documented, although the underlying molecular mechanisms are not completely defined.
We have investigated the effects of desloratadine and loratadine on rhinovirus-induced ICAM-1 expression, mRNA upregulation, and promoter activation.
Cultured primary bronchial or transformed (A549) respiratory epithelial cells were pretreated with desloratadine and loratadine for 16 hours and infected with rhinovirus type 16 for 8 hours. ICAM-1 surface expression was evaluated with flow cytometry, and ICAM-1 mRNA was evaluated with specific RT-PCR. In A549 cells promoter activation was evaluated with a chloramphenicol acetyltransferase assay, and binding activity of nuclear factor kappa B in nuclear extracts was evaluated with an electrophoretic mobility shift assay.
Desloratadine and loratadine (0.1-10 micromol/L) inhibited rhinovirus-induced ICAM-1 upregulation in both primary bronchial or transformed (A549) respiratory epithelial cells. In A549 cells the 2 compounds showed a dose-dependent inhibition with similar efficacy (inhibitory concentration of 50%, 1 micromol/L). Desloratadine and loratadine also inhibited ICAM-1 mRNA induction caused by rhinovirus infection in a dose-dependent manner, and they completely inhibited rhinovirus-induced ICAM-1 promoter activation. Desloratadine also inhibited rhinovirus-induced nuclear factor kappa B activation. Desloratadine and loratadine had no direct effect on rhinovirus infectivity and replication in cultured epithelial cells.
These effects are unlikely to be mediated by H(1)-receptor antagonism and suggest a novel mechanism of action that may be important for the therapeutic control of virus-induced asthma exacerbations.
鼻病毒最近被认为与大多数目前治疗方法难以控制的哮喘加重发作有关。细胞间黏附分子1(ICAM - 1)在哮喘气道炎症中起核心作用,并且它是90%鼻病毒的受体。气道上皮细胞的鼻病毒感染可诱导ICAM - 1产生。地氯雷他定和氯雷他定属于新型H(1)受体阻滞剂。尽管其潜在分子机制尚未完全明确,但最近已证实抗组胺药具有抗炎特性。
我们研究了地氯雷他定和氯雷他定对鼻病毒诱导的ICAM - 1表达、mRNA上调及启动子激活的影响。
将原代培养的支气管上皮细胞或转化的(A549)呼吸道上皮细胞用地氯雷他定和氯雷他定预处理16小时,然后用16型鼻病毒感染8小时。用流式细胞术评估ICAM - 1的表面表达,用特异性逆转录聚合酶链反应(RT - PCR)评估ICAM - 1 mRNA。在A549细胞中,用氯霉素乙酰转移酶试验评估启动子激活,用电泳迁移率变动分析评估核提取物中核因子κB的结合活性。
地氯雷他定和氯雷他定(0.1 - 10 μmol/L)在原代支气管上皮细胞或转化的(A549)呼吸道上皮细胞中均抑制鼻病毒诱导的ICAM - 1上调。在A549细胞中,这两种化合物表现出剂量依赖性抑制,且效果相似(半数抑制浓度为1 μmol/L)。地氯雷他定和氯雷他定还以剂量依赖性方式抑制鼻病毒感染引起的ICAM - 1 mRNA诱导,并且它们完全抑制鼻病毒诱导的ICAM - 1启动子激活。地氯雷他定还抑制鼻病毒诱导的核因子κB激活。地氯雷他定和氯雷他定对培养的上皮细胞中鼻病毒的感染性和复制无直接影响。
这些作用不太可能通过H(1)受体拮抗作用介导,提示一种新的作用机制,这可能对病毒诱导的哮喘加重发作的治疗控制具有重要意义。